Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Because poor adherence to GLP-1 receptor agonists may limit the long ... Wegovy), or tirzepatide (Mounjaro, Zepbound) -- all of which hold indications for type 2 diabetes and chronic weight ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

Similarly, Zepbound is Mounjaro’s weight-loss counterpart ... said many of his patients report life-changing weight loss while on GLP-1 medications. “I have some veterans who have lost ...